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A number of studies have shown that patients with advanced-stage slow-growing B cell 
malignancies may be cured through nonmyeloablative allogeneic hematopoietic cell transplantation 
(NMAT). Thanks to its relatively low rate of adverse effects, NMAT can be offered also to patients 
who are ineligible for more aggressive therapies due to age or other health-related issues. The long-
term success is, however, influenced by the disease status at the time of transplantation, and 
evidence points towards the importance of being in complete remission (CR), i.e. without detectable 
tumors, when receiving NMAT. This can be achieved through various conditioning pre-treatments, 
but the development of suitable regimens for patients with chemotherapy-resistant tumors has been 
slow. Fortunately, there are other ways of attacking the malignant cells; chemoresistant tumors may 
still be sensitive to ionizing radiation, which opens up a window for pre-transplant conditioning using 
targeted radionuclide therapy. 
One such modality is radioimmunotherapy (RIT), which utilizes radiolabeled monoclonal antibodies 
for specific targeting of antigens on the tumor cells. Targets are subsequently exposed to the cell-
killing radiation that is emitted by the decaying radionuclide. Various adaptations of this technique 
have been thoroughly studied over the course of several years, pioneered in part by Fred Hutch's Dr. 
Oliver Press and colleagues at the Clinical Research Division. Positive outcomes with RIT-
augmented NMAT have been reported by several research teams for patients with indolent disease, 
but a formal comparison between this approach and standard conditioning was not performed until 
very recently. 
To examine whether early CR and better long-term outcomes can be achieved through RIT 
conditioning, Drs. Ryan Cassaday, Ajay Gopal and colleagues in the Medical Director's Office 
(SCCA and Clinical Research Division) conducted a study of a group of patients with persistent 
indolent B cell non-Hodgkin lymphoma (iB-NHL) or chronic lymphocytic leukemia (CLL) that had 
received standard NMAT treatment at the Hutch between 1998 and 2009. The chosen patients then 
served as a control group to RIT-augmented transplants, based on eligibility criteria for a previously 
published RIT-NMAT phase II study targeting CD20 (Gopal et al. 2011). The results of the 
comparison were recently published in Biology of Blood and Marrow Transplantation. 
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A total of 89 patients were studied, all of them at least 18 years old and with detectable disease at 
the time of transplant. Of them, 18 had received RIT-NMAT whereas 71 were not enrolled in the 
phase II trial due to reasons other than eligibility (insurance denial, patient preferences etc.). All 89 
were pre-treated with fludarabine and total body irradiation; in addition, the anti-CD20-RIT group was 
administered rituximab and 
90
Y-ibritumomab tiuxetan two weeks prior to transplantation. 
Treatment outcome was evaluated in terms of progression-free survival (lack of relapse, progression 
or death from any cause), overall survival and nonrelapse mortality, with a median follow-up of 6.8 
years for the entire cohort. In general, the RIT-treated patients showed more high-risk features 
compared with the control group, such as chemoresistance, bulky disease, unfavorable HCT-
comorbidity index scores and low platelet counts prior to transplant. The investigators accounted for 
this imbalance through multivariate statistical analysis and demonstrated significantly improved 
progression-free survival and overall survival in the RIT-treated group. Notably, addition of RIT was 
the only factor that was significantly associated with the observed improvements. Neither nonrelapse 
mortality nor incidence of acute or chronic graft-versus-host disease differed significantly between 
the two treatment groups. 
Although the sample size was modest, the results were no less encouraging: 46% of the treated 
patients were still alive and progression-free three years after NMAT, despite persistent disease. 
This indicates that patients who traditionally have been excluded from transplant regimens also may 
benefit from the treatment. "Our data demonstrate that transplantation can be effective in patients 
unable to achieve complete remission, an important finding to reassure patients and their physicians 
that this remains a viable approach", said Dr. Cassaday, emphasizing the incentive to move forward 
with RIT conditioning protocols. "The observation that the addition of standard radioimmunotherapy 
further improved outcomes provides compelling evidence to support the study or potential clinical 
use of this approach." 
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Kaplan-Meier curves of progression-
free survival (PFS) and overall 
survival (OS) in the control and 
radioimmunotherapy (RIT) groups. 
The solid lines represent the 
observed outcomes and the dashed 
lines represent estimates adjusted 
with regard to the imbalance in high-
risk features within the two patient 
populations. At the bottom is a 
schematic visualizing the RIT 
concept. 
 
